Peripheral blood-derived endothelial progenitor cell therapy prevented deterioration of chronic kidney disease in rats

American Journal of Translational Research

Volumn 7, Issue 5, 2015, Pages 804-824

  Huang, Tien Hung ^a   Chen, Yen Ta ^a   Sung, Pei Hsun ^a   Chiang, Hsin Ju ^a   Chen, Yung Lung ^a   Chai, Han Tan ^a   Chung, Sheng Ying ^a   Tsai, Tzu Hsien ^a   Yang, Chih Chao ^a   Chen, Chih Hung ^a   Chen, Yi Ling ^a   Chang, Hsueh Wen ^b   Sun, Cheuk Kwan ^c   Yip, Hon Kan ^a,d  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

^c I SHOU UNIVERSITY   (Taiwan)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

5 6 nephrectomy; Angiogenesis; Apoptosis; Chronic kidney disease; Infammation; Oxidative stress

Indexed keywords

CASPASE 3; CD31 ANTIGEN; CD34 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; CREATININE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GELATINASE B; HYPOXIA INDUCIBLE FACTOR 1ALPHA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN KINASE B; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 1; SMAD3 PROTEIN; STROMAL CELL DERIVED FACTOR 1ALPHA; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ADULT; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; ECHOGRAPHY; ENDOTHELIAL PROGENITOR CELL; FIBROSIS; FLOW CYTOMETRY; IMMUNOFLUORESCENCE TEST; INFLAMMATION; KIDNEY BLOOD FLOW; KIDNEY PARENCHYMA; KIDNEY PARENCHYMAL INJURY SCORE; MALE; NEPHRECTOMY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATIVE STRESS; PERIPHERAL BLOOD DERIVED ENDOTHELIAL PROGENITOR CELL; RAT; RENAL SYSTEM PARAMETERS; UREA NITROGEN BLOOD LEVEL; WESTERN BLOTTING;

RATTUS; RODENTIA;

EID: 84936758606     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. [1] Go AS, Chertow GM, Fan D, McCulloch CE and Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospital-ization. N Engl J Med 2004; 351: 1296-1305.
2. [2] Hsu CC, Hwang SJ, Wen CP, Chang HY, Chen T, Shiu RS, Horng SS, Chang YK and Yang WC. High prevalence and low awareness of CKD in Taiwan: a study on the relationship between serum creatinine and awareness from a nationally representative survey. Am J Kidney Dis 2006; 48: 727-738.
3. [3] Kuo HW, Tsai SS, Tiao MM and Yang CY. Epide-miological features of CKD in Taiwan. Am J Kidney Dis 2007; 49: 46-55.
4. [4] Laliberte F, Bookhart BK, Vekeman F, Corral M, Duh MS, Bailey RA, Piech CT and Lefebvre P. Direct all-cause health care costs associated with chronic kidney disease in patients with diabetes and hypertension: a managed care perspective. J Manag Care Pharm 2009; 15: 312-322.
5. [5] Mende CW. Application of direct renin inhibition to chronic kidney disease. Cardiovasc Drugs Ther 2010; 24: 139-149.
6. [6] Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW and Cooper ME. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000; 321: 1440-1444.
7. [7] Shroff GR, Solid CA and Herzog CA. Response to letter regarding article, “Long-term survival and repeat coronary revascularization in dialysis patients after surgical and percutaneous coronary revascularization with drug-eluting and bare metal stents in the United States”. Circulation 2013; 128: e407.
8. [8] Viberti G, Wheeldon NM and MicroAlbuminuria Reduction With VSI. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002; 106: 672-678.
9. [9] Al Suwaidi J, Reddan DN, Williams K, Pieper KS, Harrington RA, Califf RM, Granger CB, Ohman EM, Holmes DR; GUSTO-IIb, GUSTO-III, PURSUIT. Global Use of Strategies to Open Occluded Coronary Arteries. Platelet Glycopro-tein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy; PARAGON-A Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Global Organization Network. Prognostic implications of abnormalities in renal function in patients with acute coronary syndromes. Circulation 2002; 106: 974-980.
10. [10] Fried LF, Orchard TJ and Kasiske BL. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int 2001; 59: 260-269.
11. [11] Reis SE, Olson MB, Fried L, Reeser V, Mankad S, Pepine CJ, Kerensky R, Merz CN, Sharaf BL, Sopko G, Rogers WJ and Holubkov R. Mild renal insufficiency is associated with angio-graphic coronary artery disease in women. Circulation 2002; 105: 2826-2829.
12. [12] Tonelli M, Moye L, Sacks FM, Kiberd B, Curhan G, Cholesterol and Recurrent Events Trial I. Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Ann Intern Med 2003; 138: 98-104.
13. [13] Basile DP. The transforming growth factor beta system in kidney disease and repair: recent progress and future directions. Curr Opin Nephrol Hypertens 1999; 8: 21-30.
14. [14] Cybulsky AV. Growth factor pathways in prolif-erative glomerulonephritis. Curr Opin Nephrol Hypertens 2000; 9: 217-223.
15. [15] El-Nahas AM. Plasticity of kidney cells: role in kidney remodeling and scarring. Kidney Int 2003; 64: 1553-1563.
16. [16] Flanders KC. Smad3 as a mediator of the f-brotic response. Int J Exp Pathol 2004; 85: 47-64.
17. [17] Yang CS, Lin CH, Chang SH and Hsu HC. Rapidly progressive fbrosing interstitial nephritis associated with Chinese herbal drugs. Am J Kidney Dis 2000; 35: 313-318.
18. [18] Leu S, Sun CK, Sheu JJ, Chang LT, Yuen CM, Yen CH, Chiang CH, Ko SF, Pei SN, Chua S, Youssef AA, Wu CJ and Yip HK. Autologous bone marrow cell implantation attenuates left ventricular remodeling and improves heart function in porcine myocardial infarction: an echocardiographic, six-month angiographic, and molecular-cellular study. Int J Cardiol 2011; 150: 156-168.
19. [19] Tang XL, Rokosh G, Sanganalmath SK, Yuan F, Sato H, Mu J, Dai S, Li C, Chen N, Peng Y, Dawn B, Hunt G, Leri A, Kajstura J, Tiwari S, Shirk G, Anversa P and Bolli R. Intracoronary administration of cardiac progenitor cells alleviates left ventricular dysfunction in rats with a 30-day-old infarction. Circulation 2010; 121: 293-305.
20. [20] Wolf D, Reinhard A, Seckinger A, Katus HA, Kuecherer H and Hansen A. Dose-dependent effects of intravenous allogeneic mesenchy-mal stem cells in the infarcted porcine heart. Stem Cells Dev 2009; 18: 321-329.
21. [21] Assmus B, Rolf A, Erbs S, Elsässer A, Haber-bosch W, Hambrecht R, Tillmanns H, Yu J, Corti R, Mathey DG, Hamm CW, Süselbeck T, Tonn T, Dimmeler S, Dill T, Zeiher AM, Schächinger V; REPAIR-AMI Investigators. Clinical outcome 2 years after intracoronary administration of bone marrow-derived progenitor cells in acute myocardial infarction. Circ Heart Fail 2010; 3: 89-96.
22. [22] Iwasaki H, Kawamoto A, Ishikawa M, Oyamada A, Nakamori S, Nishimura H, Sadamoto K, Ho-rii M, Matsumoto T, Murasawa S, Shibata T, Suehiro S and Asahara T. Dose-dependent contribution of CD34-positive cell transplantation to concurrent vasculogenesis and cardio-myogenesis for functional regenerative recovery after myocardial infarction. Circulation 2006; 113: 1311-1325.
23. [23] Kang HJ, Kim HS, Zhang SY, Park KW, Cho HJ, Koo BK, Kim YJ, Soo Lee D, Sohn DW, Han KS, Oh BH, Lee MM and Park YB. Effects of intra-coronary infusion of peripheral blood stem-cells mobilised with granulocyte-colony stimulating factor on left ventricular systolic function and restenosis after coronary stenting in myo-cardial infarction: the MAGIC cell randomised clinical trial. Lancet 2004; 363: 751-756.
24. [24] Schächinger V, Assmus B, Erbs S, Elsässer A, Haberbosch W, Hambrecht R, Yu J, Corti R, Mathey DG, Hamm CW, Tonn T, Dimmeler S, Zeiher AM; REPAIR-AMI investigators. Intracor-onary infusion of bone marrow-derived mono-nuclear cells abrogates adverse left ventricular remodelling post-acute myocardial infarction: insights from the reinfusion of enriched progenitor cells and infarct remodelling in acute myocardial infarction (REPAIR-AMI) trial. Eur J Heart Fail 2009; 11: 973-979.
25. [25] Tendera M, Wojakowski W, Ruzyłło W, Cho-jnowska L, Kepka C, Tracz W, Musiałek P, Pi-wowarska W, Nessler J, Buszman P, Grajek S, Breborowicz P, Majka M, Ratajczak MZ; REGENT Investigators. Intracoronary infusion of bone marrow-derived selected CD34+CXCR4+ cells and non-selected mononuclear cells in patients with acute STEMI and reduced left ventricular ejection fraction: results of randomized, multicentre Myocardial Regeneration by Intracoronary Infusion of Selected Population of Stem Cells in Acute Myocardial Infarction (REGENT) Trial. Eur Heart J 2009; 30: 1313-1321.
26. [26] Jie KE, Zaikova MA, Bergevoet MW, Wester-weel PE, Rastmanesh M, Blankestijn PJ, Boer WH, Braam B and Verhaar MC. Progenitor cells and vascular function are impaired in patients with chronic kidney disease. Nephrol Dial Transplant 2010; 25: 1875-1882.
27. [27] Krenning G, Dankers PY, Drouven JW, Waanders F, Franssen CF, van Luyn MJ, Harm-sen MC and Popa ER. Endothelial progenitor cell dysfunction in patients with progressive chronic kidney disease. Am J Physiol Renal Physiol 2009; 296: F1314-1322.
28. [28] Chen YT, Cheng BC, Ko SF, Chen CH, Tsai TH, Leu S, Chang HW, Chung SY, Chua S, Yeh KH, Chen YL and Yip HK. Value and level of circulating endothelial progenitor cells, angiogenesis factors and mononuclear cell apoptosis in patients with chronic kidney disease. Clin Exp Nephrol 2013; 17: 83-91.
29. [29] Sun CK, Lin YC, Yuen CM, Chua S, Chang LT, Sheu JJ, Lee FY, Fu M, Leu S and Yip HK. Enhanced protection against pulmonary hypertension with sildenafl and endothelial progenitor cell in rats. Int J Cardiol 2012; 162: 45-58.
30. [30] Yeh KH, Sheu JJ, Lin YC, Sun CK, Chang LT, Kao YH, Yen CH, Shao PL, Tsai TH, Chen YL, Chua S, Leu S and Yip HK. Beneft of combined extra-corporeal shock wave and bone marrow-derived endothelial progenitor cells in protection against critical limb ischemia in rats. Crit Care Med 2012; 40: 169-177.
31. [31] Yip HK, Chang LT, Sun CK, Sheu JJ, Chiang CH, Youssef AA, Lee FY, Wu CJ and Fu M. Autolo-gous transplantation of bone marrow-derived endothelial progenitor cells attenuates mono-crotaline-induced pulmonary arterial hypertension in rats. Crit Care Med 2008; 36: 873-880.
32. [32] Chen HH, Lin KC, Wallace CG, Chen YT, Yang CC, Leu S, Chen YC, Sun CK, Tsai TH, Chen YL, Chung SY, Chang CL and Yip HK. Additional beneft of combined therapy with melatonin and apoptotic adipose-derived mesenchymal stem cell against sepsis-induced kidney injury. J Pineal Res 2014; 57: 16-32.
33. [33] Chen YT, Sun CK, Lin YC, Chang LT, Chen YL, Tsai TH, Chung SY, Chua S, Kao YH, Yen CH, Shao PL, Chang KC, Leu S and Yip HK. Adipose-derived mesenchymal stem cell protects kidneys against ischemia-reperfusion injury through suppressing oxidative stress and in-fammatory reaction. J Transl Med 2011; 9: 51.
34. [34] Yip HK, Chang YC, Wallace CG, Chang LT, Tsai TH, Chen YL, Chang HW, Leu S, Zhen YY, Tsai CY, Yeh KH, Sun CK and Yen CH. Melatonin treatment improves adipose-derived mesen-chymal stem cell therapy for acute lung isch-emia-reperfusion injury. J Pineal Res 2013; 54: 207-221.
35. [35] Chade AR, Zhu X, Lavi R, Krier JD, Pislaru S, Simari RD, Napoli C, Lerman A and Lerman LO. Endothelial progenitor cells restore renal function in chronic experimental renovascular disease. Circulation 2009; 119: 547-557.
36. [36] Sangidorj O, Yang SH, Jang HR, Lee JP, Cha RH, Kim SM, Lim CS and Kim YS. Bone marrow-derived endothelial progenitor cells confer renal protection in a murine chronic renal failure model. Am J Physiol Renal Physiol 2010; 299: F325-335.